New drug cocktail targets Hard-to-Treat stomach cancer
NCT ID NCT06947291
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a combination of two drugs—glumetinib (a targeted therapy) and a special form of docetaxel (chemotherapy)—in people with advanced stomach cancer or other solid tumors that have a specific genetic marker called MET overexpression. The trial has two stages: first to find the best dose, then to see if the combo shrinks tumors. About 350 adults are being recruited across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glumetinib tablets and docetaxel (albumin-bound) injection
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced gastric cancer that has MET overexpression, potentially shrinking tumors and delaying progression.
What could go wrong
This is an early-phase trial (Phase 2) with a small number of participants, so results may not apply to everyone. The combination may cause side effects like fatigue, low blood counts, or allergic reactions, and it may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
Contact Email: •••••@•••••